Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City
About Myriad Genetics, Inc.Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.
CEO and Founder: Mark Capone
CMO (Medical): Richard Wenstrup
CFO: Bryan Riggsbee
CSO (Scientific): Jerry Lanchbury
Please click here for Myriad Genetics job opportunities.
Please click here for clinical trial information.
FOLLOW MYRIAD GENETICS:
Tweets by Myriad Genetics
500 articles with Myriad Genetics, Inc.
Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer
65 Percent of Patients Remained on Active Surveillance for More than Four Years
Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention
More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Myriad Genetics, Inc. ("Myriad" or the "Company") (NASDAQ: MYGN).
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
Myriad Genetics, Inc. announced that the AstraZeneca/Merck Phase III PROfound studydemonstrated that men with metastatic castration-resistant prostate cancer who tested positive for germline and somatic mutations in homologous recombination repair genes benefitted from treatment with Lynparza®, a novel PARP inhibitor.
Kroger Health, the healthcare arm of The Kroger Co. providing health, wellness, and nutrition solutions to more than 14 million people nationwide, announced its partnership with Myriad Genetics to pilot Myriad Genetics' GeneSight® pharmacogenomic test with Kroger Health Plan members.
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer
Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that The Pharmacogenomics Journal published the results of the first comprehensive cost-effectiveness analysis of the EndoPredict® test compared to other breast cancer assays.
Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan
Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced the Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad’s BRACAnalysis® Diagnostic System (i.e., “BRACAnalysis”) as a companion diagnostic with the PARP inhibitor, Lynparza® (olaparib)
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that results from two studies of the myRisk® Hereditary Cancer test will be featured today in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO).
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine,today announced that its BRACAnalysis CDx® companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with Lynparza® (olaparib) in the Phase III POLO study.
Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has found that EndoPredict® test accurately predicts which women with ER-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy.
= Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from several studies at the 2019 Annual Clinical and Scientific meeting of The American College of Obstetricians and Gynecologists (ACOG) being held May 3-6, 2019 in Nashville, Tenn.
Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has submitted the first module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® HRD CDx test.
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine,today announced that it has expanded its companion diagnostic collaboration with AstraZeneca and Merck (known as MSD outside the US and Canada).
Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present results from two important studies at the 2019 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that highlight the performance of its prenatal tests.
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the myPath® Melanoma test to help physicians provide a definitive diagnosis when a suspicious skin lesion is equivocal based upon histopathology.
Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib
Myriad Will Seek FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Olaparib in this Patient Population
Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced the publication of an important clinical study regarding its Vectra® test in Current Medical Research & Opinion.